Alaunos Therapeutics, Inc. (TCRT) — Financial statements
Income statement, balance sheet, and cash flow for Alaunos Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.01↓50.0% | 0.01↑100.0% | 0.01↓99.8% | 3↑634.2% | 0.40 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 5 | 0.00 | 0.00 | |
| Gross Profit | 0.01↓50.0% | 0.01↑100.2% | -5↓264.2% | 3↑634.2% | 0.40 | |
| Operating Expenses | ||||||
| R&D Expenses | 1↑276.5% | 0.36↓97.8% | 16↓34.9% | 25↓49.6% | 50 | |
| General & Administrative Expenses | 3↓35.7% | 4↓63.5% | 12↓7.0% | 13↓52.3% | 28 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↓35.7% | 4↓63.5% | 12↓7.0% | 13↓52.3% | 28 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.97↑830.1% | -0.13↓118.0% | 0.74 | |
| Operating Expenses | 4↓12.3% | 5↓83.6% | 29↓22.5% | 38↓51.2% | 78 | |
| Total Costs & Expenses | 4↓12.3% | 5↓85.9% | 34↓9.9% | 38↓51.2% | 78 | |
| Operating Results | ||||||
| Operating Income | -4↑12.2% | -5↑86.0% | -34↑2.4% | -35↑54.7% | -78 | |
| Depreciation & Amortization | 0.01↑250.0% | 0.00↓99.9% | 2↓16.1% | 3↑6.2% | 3 | |
| EBITDA | -4↑9.7% | -5↑84.9% | -31↑2.9% | -32↑57.6% | -75 | |
| EBIT | -4↑9.7% | -5↑85.9% | -33↑3.9% | -35↑55.4% | -78 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00↑100.0% | -2↑39.1% | -3↓165.3% | -1 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 2↓39.1% | 3↑165.3% | 1 | |
| Non-Operating Income | 0.00↑100.0% | -0.13↑87.3% | -1↓98.1% | -0.53↓4169.2% | 0.01 | |
| Other Income / Expenses | 0.05↓63.2% | 0.13↑115.2% | -0.87↑66.7% | -3↓118.4% | -1 | |
| Income Before Tax | -4↑10.8% | -5↑86.7% | -35↑6.9% | -38↑52.1% | -79 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -4↑10.8% | -5↑86.7% | -35↑6.9% | -38↑52.1% | -79 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -4↑10.8% | -5↑86.7% | -35↑6.9% | -38↑52.1% | -79 | |
| Bottom-Line Net Income | -4↑10.8% | -5↑86.7% | -35↑6.9% | -38↑52.1% | -79 | |
| EPS (Basic) | -2.20↑24.7% | -2.92↑86.7% | -21.97↑15.4% | -25.97↑51.7% | -53.80 | |
| EPS (Diluted) | -2.20↑24.7% | -2.92↑86.7% | -21.97↑15.4% | -25.97↑51.7% | -53.80 | |
| Weighted Average Shares | 2↑21.7% | 2↑0.1% | 2↑10.5% | 1↑1.3% | 1 | |
| Weighted Average Diluted Shares | 2↑21.7% | 2↑0.1% | 2↑10.5% | 1↑1.3% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.